ALS White Paper
The Predictable Medicine Company™
Unravel Biosciences Newsletter
Unravel Biosciences kicked off the new year with a busy start. Our Predictable Medicine™ innovation stack, including BioNAV™ and Living Molecular Twins™, has begun to enable more and more advancements in drug development. In this newsletter, read updates on our RVL-001 clinical trials, our partnership with Evogene, and our newest white paper, which details how BioNAV™ addresses highly heterogeneous disorders.
RLV-001 Clinical Trials: Site Initiation
Our CEO, Richard Novak, and CMO, Neal Muni, recently visited Medellin, Colombia, to initiate our clinical trial site. The site will be used for two clinical trials: Rett syndrome and Pitt Hopkins syndrome to evaluate RVL-001 in placebo-controlled, single-blind clinical trials.
Watch below to learn from Richard, Neal, and our Clinical Operations Director, Carlos Capparos about the clinical trial site at PECET, Universidad de Antioquia.
Colombia Site Initiation 2026
Visit our YouTube page for more video content.
Announcing Evogene-Unravel partnership to develop new drugs for demyelinating disorders
We recently began our partnership with Evogene, aimed at addressing high unmet need for patients with demyelinating diseases. This collaboration reflects our platform, BioNAV™’s, ability to discover novel drug targets using real patient data and deep insights that are enabled by our datamine. By combining our efforts with Evogene’s ChemPass AI™, we will create meaningful solutions for the Multiple Sclerosis and demyelinating disease community.
Read more about our collaboration in our recent press release.
Unravel's approach makes therapeutic development for complex diseases manageable in "ALS Unraveled"
Our newest white paper, "ALS Unraveled: A patient-centric approach to drug discovery and clinical validation," breaks down Unravel's unique capability of stratifying patient populations based on response to therapeutics. While Unravel's approach can be applied to any disorder, its capabilities are most valuable in highly complex and heterogeneous disorders like Amyotrophic Lateral Sclerosis.
One of the leading causes of clinical trial failure in large neurodegenerative disorders is that large disorders are comprised of distinct patient subgroups, all averaged together in the studies. We believe we need to match drug candidates to specific patients based on their molecular data, not a shared diagnosis, to improve clinical outcomes in these devastating disorders.
Unravel's Predictable Medicine™ innovation stack can enable effective therapeutics despite the historical challenges and setbacks faced with traditional drug development.
Read Our ALS White Paper
Visit our LinkedIn Page
